Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news...

BioSante Pharma (NASDAQ:BPAX)

LibiGel (testosterone) - Pivotal Phase 3 Clinical Trials under SPA

- expected NDA filing in 2011, Phase 3 long-term safety study plus two Phase 3 efficacy trials ongoing for sexual dysfunction post-menopausal women, expects to make decision during 4Q10 on enrollment status safety study, on 7/13/10 initiated six-month study to evaluate effect on cognitive function

EntreMed (NASDAQ:ENMDD)

ENMD-2076 (a selective angiogenic kinase inhibitor anti-cancer agent) - Phase 2 Clinical Trial, Preclinical Data

On 4/13/10, initiated Phase 2 study in patients with platinum-resistant ovarian cancer with ClinicalTrials.gov ID NCT01104675 and results expected during 1Q11, six sites are actively recruiting patients, reported anti-cancer effect in preclinical multiple myeloma (MM) models on 7/13/10

Protalix Biotherapeutics (AMEX:PLX)

UPLYSO (taliglucerase alfa) (a plant-cell expressed form of the enzyme, gluco-cerebrosidase) received a temporary authorization for use in France today, following news on Monday that the FDA accepted the Company's NDA with a standard 10-month review and PDUFA action goal data in late February 2011.

Lorillard (NYSE:LO) - Newport Brand of Menthol Cigarettes

FDA Tobacco Products Scientific Advisory Panel Ruling, FDA Decision on Menthol Cigarettes

- An initial recommendation to FDA is expected March 2011 with final FDA ruling expected by March 2012, reviewing health effects of menthol cigarettes (which account for approx. 25% smokers and 33% of the $70 billion US cigarette market), a second FDA Tobacco Advisory Panel Meeting is scheduled for July 15-16 (first panel meeting was held March 2010)

Vivus (NASDAQ:VVUS) - QNEXA (phentermine plus topiramate) (once-daily combo weight loss / obesity drug candidate)

- Five potential safety concerns (neuro-psychiatric) outlined in briefing docs ahead of 7/15/10 Endocrinologic and Metabolic Drugs Advisory Panel Meeting, no efficacy concerns based on weight loss observed in pivotal studies, PDUFA action goal date 10/28/10 under standard 10-month review

Immunovaccine (IMV.V) - EMD 640744 (surviving-based therapeutic cancer vaccine) formulated with DepoVax delivery system

- On 7/12/10, announced in-licensing from Merck KGaA (OTC:MKGAY), pending Phase I/II clinical trial estimated to begin by year-end 2010 targeting multiple solid tumors and blood-based cancers (melanoma, prostate, pancreatic, colon and multiple myeloma.

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials.

The actively managed HavRx Regulatory Catalyst Index update report is currently tracking 598 entries and 402 companies (with approximately 200 stocks trading under $5 per share and 61 private companies). Subscribers also have access to my real money portfolio tracker, Google Calendar event tracking for over 1,000 stocks in the HavRx Indexes, and real-time trading / article updates on the member forum. Click on the following email archive web link for a 50% discount ($150) promo code off the regular one-year, non-recurring subscription price... http://eepurl.com/HFmF 

Disclosure: No positions